Xlife Sciences AG/ CH0461929603 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 171.03 mill.EUR | - | - |
Fundamentals
FY 2023 | Growth (1Y) | |
---|---|---|
Per Share | ||
Earnings per Share: | 2.73 CHF | 0.37% |
EPS Diluted: | - CHF | 4.00% |
Revenues per Share: | 0.18 CHF | -9.15% |
Book Value per Share: | 47.95 CHF | 7.71% |
Cash Flow per Share: | 0.03 CHF | - |
Dividend per Share: | - CHF | - |
Total | in mill. | |
Revenues: | 0.99 CHF | -3.85% |
Net Income: | 14.88 CHF | 3.96% |
Operating Cash Flow: | 0.17 CHF | - |
Cash and Cash Equivalents: | 0.22 CHF | - |
Valuation Ratios
Current | Latest FY* | |
---|---|---|
P/E Ratio: | 10.48 | 18.28 |
P/S Ratio: | 161.81 | 282.32 |
P/BV ratio: | 0.60 | 1.04 |
P/CF Ratio: | 931.05 | 1,624.46 |
PEG: | 28.50 | 49.72 |
Earnings Yield: | 9.55% | 5.47% |
Dividend Yield: | - | - |
Market Capitalization | ||
Market Capitalization: | 171.03 mill. EUR | 300.47 mill. EUR |
Free Float Market Cap.: | - EUR | - EUR |
Market Cap. / Employee: | - EUR | - EUR |
Shares Outstanding: | 5.59 mill. |
Profitability
Gross Profit Margin: | 45.43% |
EBIT Margin: | -2,054.56% |
Net Profit Margin: | 1,505.34% |
Return on Equity: | 5.55% |
Return on Assets: | 2.91% |
Financial Strength
Liquidity I / Cash Ratio: | 3.75% |
Liquidity II / Quick Ratio: | 160.25% |
Liquidity III / Current Ratio: | 310.67% |
Debt / Equity Ratio: | 90.92% |
Dynam. Debt / Equity Ratio: | 141,934.48% |
Efficiency
Employees: | - |
Personal Expenses / Employee: | - CHF |
Revenues / Employee: | - CHF |
Net Income / Employee: | - CHF |
Total Assets / Employee: | - CHF |
* Fiscal Year End: | 2023-12-31 |
Accounting Standard: | IFRS |
Currency: | CHF |